Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan M Gewirtz

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Investigation|December 7, 2007
On future's doorstep: RNA interference and the pharmacopeia of tomorrowAlan M Gewirtz
Blood Cells, Molecules & Diseases|January 12, 2007
RNA targeted therapeutics for hematologic malignanciesAlan M Gewirtz
Blood|November 3, 2009
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cellsAnna Kalota, Alan M Gewirtz
Nature Reviews. Drug Discovery|July 18, 2002
Nucleic-acid therapeutics: basic principles and recent applicationsJoanna B Opalinska, Alan M Gewirtz
The Journal of Allergy and Clinical Immunology|January 12, 2010
Embryonic and adult stem cell therapyAnne C Brignier, Alan M Gewirtz
Science'S STKE : Signal Transduction Knowledge Environment|October 30, 2003
Therapeutic potential of antisense nucleic acid moleculesJoanna B Opalinska, Alan M Gewirtz
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Nucleic acid therapeutics: a work in progressJoanna B Opalinska, Alan M Gewirtz
Expert Opinion on Biological Therapy|December 2, 2005
RNA interference for treating haematological malignanciesElizabeth O Hexner, Alan M Gewirtz
The Journal of Biological Chemistry|November 24, 2011
The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemiaHuiwu Zhao, Shenghao Jin, Alan M Gewirtz
Cancer Biology & Therapy|January 17, 2004
Progress in the development of nucleic acid therapeutics for cancerAnna Kalota, Susan E Shetzline, Alan M Gewirtz
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|December 7, 2007
On future's doorstep: RNA interference and the pharmacopeia of tomorrowAlan M Gewirtz
Blood Cells, Molecules & Diseases|January 12, 2007
RNA targeted therapeutics for hematologic malignanciesAlan M Gewirtz
Blood|November 3, 2009
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cellsAnna Kalota, Alan M Gewirtz
Nature Reviews. Drug Discovery|July 18, 2002
Nucleic-acid therapeutics: basic principles and recent applicationsJoanna B Opalinska, Alan M Gewirtz
The Journal of Allergy and Clinical Immunology|January 12, 2010
Embryonic and adult stem cell therapyAnne C Brignier, Alan M Gewirtz
Science'S STKE : Signal Transduction Knowledge Environment|October 30, 2003
Therapeutic potential of antisense nucleic acid moleculesJoanna B Opalinska, Alan M Gewirtz
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Nucleic acid therapeutics: a work in progressJoanna B Opalinska, Alan M Gewirtz
Expert Opinion on Biological Therapy|December 2, 2005
RNA interference for treating haematological malignanciesElizabeth O Hexner, Alan M Gewirtz
The Journal of Biological Chemistry|November 24, 2011
The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemiaHuiwu Zhao, Shenghao Jin, Alan M Gewirtz
Cancer Biology & Therapy|January 17, 2004
Progress in the development of nucleic acid therapeutics for cancerAnna Kalota, Susan E Shetzline, Alan M Gewirtz
Pageof 4